Clinical Data Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer BioSpaceA triplet regimen comprising Merck's Welireg and PD-1 blockbuster Keytruda and Eisai's Lenvima flopped in a Phase 3 renal cell carcinoma trial.Clinical DataOncologyRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) BioSpace A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal cell carcinoma trial. Clinical DataOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Novo Nordisk preps filings for sickle cell drug etavopivatNext: Tortugas takes neuro deep dive with $106M to develop Eisai, Hansoh programs Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
